State of Alaska Department of Revenue Sells 4,423 Shares of ICU Medical, Inc. $ICUI

State of Alaska Department of Revenue trimmed its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 45.6% during the third quarter, HoldingsChannel reports. The firm owned 5,269 shares of the medical instruments supplier’s stock after selling 4,423 shares during the quarter. State of Alaska Department of Revenue’s holdings in ICU Medical were worth $845,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ICUI. Allworth Financial LP bought a new stake in shares of ICU Medical in the 2nd quarter valued at $26,000. Hilton Head Capital Partners LLC raised its stake in ICU Medical by 52.0% during the 1st quarter. Hilton Head Capital Partners LLC now owns 336 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 115 shares during the period. Versant Capital Management Inc raised its stake in ICU Medical by 26.2% during the 3rd quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 65 shares during the period. Public Employees Retirement System of Ohio bought a new position in ICU Medical during the second quarter worth about $51,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 146 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insiders Place Their Bets

In other news, insider Ben Sousa sold 2,250 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total value of $401,220.00. Following the sale, the insider owned 3,076 shares of the company’s stock, valued at $548,512.32. The trade was a 42.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel Woolson sold 5,417 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the transaction, the vice president owned 17,062 shares of the company’s stock, valued at $3,093,852.46. The trade was a 24.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,830 shares of company stock valued at $3,905,003 over the last 90 days. 2.10% of the stock is currently owned by company insiders.

ICU Medical Stock Down 0.1%

Shares of ICU Medical stock opened at $160.84 on Thursday. The firm has a market cap of $4.02 billion, a PE ratio of 136.31, a P/E/G ratio of 2.03 and a beta of 0.86. The business’s 50 day simple moving average is $166.36 and its 200 day simple moving average is $150.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. ICU Medical, Inc. has a 52-week low of $113.37 and a 52-week high of $192.85.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The business’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, analysts predict that ICU Medical, Inc. will post 7.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ICUI. KeyCorp boosted their target price on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research note on Tuesday, July 21st. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Needham & Company LLC raised their target price on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Piper Sandler raised their target price on shares of ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $192.80.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.